• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

    4/3/24 6:00:00 AM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance
    Get the next $GS alert in real time by email

    Proceeds support advancement of two next-generation precision oncology programs into clinical development within 12 months

    Financing led by Goldman Sachs Alternatives with participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and existing investors

    Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing. Proceeds from the fundraise will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor.

    The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Concurrent with the financing, Josh Richardson, M.D., a Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, and Uwe Schoenbeck, a Partner at Canaan Partners, were named to the Board of Directors.

    "We are pleased with a financing of this magnitude that enables Alterome to advance multiple programs into the clinic within the next 12 months," said Eric Murphy, Ph.D., co-founder and CEO of Alterome Therapeutics. "The precision oncology field has arrived at a special moment with the exciting evolution of both drug discovery and precision medicine. A unique integration of structure-guided drug discovery with deep translational biology is facilitating the development of novel therapies that address previously inaccessible proteins. We are thrilled to have the support of this visionary group of new and existing investors, who share our enthusiasm to face the challenge of targeting well-known cancer-causing mutations deemed undruggable for the previous 20 years."

    Leveraging its Kraken platform, a structure-guided machine learning approach to drug discovery, the company is advancing a pipeline of precision, small molecule therapies targeting a broad spectrum of validated oncogenic targets. Alterome's founding mission focused on mutation-selective and isoform-selective approaches designed to specifically target cancer cells over normal cells, enabling greater inhibition of key cancer drivers while simultaneously enhancing the therapeutic safety profile. The preclinical pipeline features a covalent AKT1 E17K mutation-selective inhibitor and a KRAS isoform-selective inhibitor targeting 90% of KRAS mutations including the most common mutations G12V and G12D. These two lead programs are designed for patients with limited treatment options and are expected to begin clinical testing over the next year.

    "Alterome is advancing an exciting portfolio of therapies targeting validated oncogenic drivers, with clear paths to early clinical signals," said Dr. Josh Richardson, Managing Director within Life Sciences Investing at Goldman Sachs Alternatives. "Goldman Sachs is excited to join this exceptional group of investors to support the company in delivering a new class of precision oncology drugs that enable cancer patients to live longer and better lives."

    About Alterome Therapeutics, Inc.

    Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is led by an expert team of precision oncology R&D leaders with a history of developing marketed oncology small molecule drugs.

    For more information, visit www.alterome.com.

    Follow us on LinkedIn and Twitter.

    About Goldman Sachs Alternatives

    Goldman Sachs (NYSE:GS) is one of the leading investors in alternatives globally, with over $450 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, life sciences, private credit, real estate, infrastructure, hedge funds, and sustainability. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs. The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets. The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors, and individuals. Goldman Sachs has over $2.8 trillion in assets under supervision globally as of December 31, 2023.

    Follow us on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240403342221/en/

    Get the next $GS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GS

    DatePrice TargetRatingAnalyst
    4/7/2025$558.00Overweight → Equal-Weight
    Morgan Stanley
    4/4/2025$560.00Outperform → Neutral
    Daiwa Securities
    3/19/2025Outperform → Perform
    Oppenheimer
    2/27/2025$690.00 → $660.00Outperform → Mkt Perform
    Keefe Bruyette
    1/6/2025$610.00Buy → Neutral
    UBS
    11/26/2024$569.00 → $608.00Buy → Hold
    HSBC Securities
    7/2/2024Buy → Neutral
    Seaport Research Partners
    4/16/2024$465.00Hold → Buy
    Argus
    More analyst ratings

    $GS
    SEC Filings

    See more
    • SEC Form FWP filed by Goldman Sachs Group Inc.

      FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

      7/3/25 11:56:59 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form FWP filed by Goldman Sachs Group Inc.

      FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

      7/3/25 11:48:15 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form FWP filed by Goldman Sachs Group Inc.

      FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

      7/3/25 10:36:56 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVISTA HEALTHCARE PARTNERS CLOSES CONTINUATION FUND FOR GCM

      Goldman Sachs Alternatives served as lead investor; additional investments from BlackRock Secondaries & Liquidity Solutions NEW YORK, June 24, 2025 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced the successful close of Avista Healthcare Partners CV II, L.P., a single-asset continuation fund for GCM, a leading outsourced manufacturer of complex precision components for high-growth medical technology end markets. The continuation fund, managed by Avista, is anchored by commitments from funds managed by Secondaries at Goldman Sachs Alternatives, with additional investments from funds managed by BlackRock Se

      6/24/25 4:30:00 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Goldman Sachs Asset Management Announces Liquidation of Two Exchange-Traded Funds

      Goldman Sachs Asset Management ("GSAM"), the investment adviser for the Goldman Sachs Future Consumer Equity ETF and Goldman Sachs Future Planet Equity ETF (each, a "Fund" and collectively, the "Funds"), announced today that the Funds' Board of Trustees, at the recommendation of GSAM, has approved a plan of liquidation for each Fund (collectively, the "Plans"). Under the Plans, which are effective today, the Funds will begin the process of liquidating portfolio assets and unwinding their affairs in an orderly fashion over time. The Plans are not subject to shareholder approval. Shareholders of the Funds may sell their shares on the Funds' listing exchange, NYSE Arca, Inc. ("NYSE Arca"), u

      6/18/25 4:30:00 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • BMO Launches Alpha Managers Hedge Fund, in Collaboration with Goldman Sachs Asset Management

      /NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OR TO U.S. PERSONS/ TORONTO, June 10, 2025 /CNW/ - BMO Global Asset Management ('BMO GAM') today announced the launch of its new Alpha Managers Hedge Fund ('Fund'), complementing BMO GAM's innovative suite of alternative investment strategies for accredited investors. The new fund combines high-conviction strategies from global hedge fund managers and aims to deliver alpha, low volatility and less correlated returns to traditional asset classes. BMO GAM's Alpha Managers Hedge Fund portfolio was designed in collaboration with Goldman Sachs Asset Management ('GSAM') and draws upon the combined expertise of

      6/10/25 6:00:00 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Goldman Sachs from Overweight to Equal-Weight and set a new price target of $558.00

      4/7/25 11:55:54 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Goldman Sachs downgraded by Daiwa Securities with a new price target

      Daiwa Securities downgraded Goldman Sachs from Outperform to Neutral and set a new price target of $560.00

      4/4/25 8:36:56 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Goldman Sachs downgraded by Oppenheimer

      Oppenheimer downgraded Goldman Sachs from Outperform to Perform

      3/19/25 8:14:15 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman of the Board and CEO Solomon David M sold $3,035,850 worth of shares (5,000 units at $607.17), decreasing direct ownership by 4% to 132,784 units (SEC Form 4)

      4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

      5/15/25 4:04:21 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Chairman of the Board and CEO Solomon David M converted options into 49,926 shares and covered exercise/tax liability with 27,610 shares, increasing direct ownership by 19% to 137,784 units (SEC Form 4)

      4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

      5/2/25 4:10:17 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • President and COO Waldron John E. covered exercise/tax liability with 22,339 shares and converted options into 40,395 shares, increasing direct ownership by 17% to 124,512 units (SEC Form 4)

      4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

      5/2/25 4:09:02 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hess John B bought $1,997,584 worth of shares (3,904 units at $511.68) (SEC Form 4)

      4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

      4/17/25 4:06:04 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Director Johnson Kevin R bought $1,485,648 worth of shares (2,400 units at $619.02) (SEC Form 4)

      4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

      1/21/25 4:55:51 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Director Flaherty Mark A. bought $29,545 worth of shares (82 units at $358.75) (SEC Form 4)

      4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

      10/9/24 4:12:58 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Leadership Updates

    Live Leadership Updates

    See more
    • Julie R. Smith Named Metiri Group CEO

      Smith to Lead New Era of Client-Centered Growth GENEVA, Ill., June 9, 2025 /PRNewswire/ -- Metiri Group, a leading expert and partner in environmental testing solutions, today announced the appointment of Julie R. Smith as Chief Executive Officer, effective immediately. Smith has served as interim CEO since October 2024. She takes over from Cabot Earle, who now serves as Metiri Group's Founder & Chief Strategy Officer, leading the company's M&A strategy.  These leadership changes complete Metiri Group's Executive team, with Ronald Markle serving as Chief Financial Officer and

      6/9/25 10:00:00 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Julie R. Smith Named Metiri Group CEO

      Smith to Lead New Era of Client-Centered Growth GENEVA, Ill., June 9, 2025 /PRNewswire/ -- Metiri Group, a leading expert and partner in environmental testing solutions, today announced the appointment of Julie R. Smith as Chief Executive Officer, effective immediately. Smith has served as interim CEO since October 2024. She takes over from Cabot Earle, who now serves as Metiri Group's Founder & Chief Strategy Officer, leading the company's M&A strategy.  These leadership changes complete Metiri Group's Executive team, with Ronald Markle serving as Chief Financial Officer and

      6/6/25 1:18:00 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Parexel Announces Updates to Board of Directors

      Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs Healthcare Private Equity Investing, joins as new Director.Mr. Bernstein succeeds Michael Bruun in the Goldman Sachs Board seat as part of a planned rotation.Mr. Bernstein's appointment continues Parexel's focus on advancing its strategic roadmap to deliver on the company's growth objectives. DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Parexel, one of the world's largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management

      3/5/25 9:00:00 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Financials

    Live finance-specific insights

    See more
    • Goldman Sachs Asset Management Announces Liquidation of Two Exchange-Traded Funds

      Goldman Sachs Asset Management ("GSAM"), the investment adviser for the Goldman Sachs Future Consumer Equity ETF and Goldman Sachs Future Planet Equity ETF (each, a "Fund" and collectively, the "Funds"), announced today that the Funds' Board of Trustees, at the recommendation of GSAM, has approved a plan of liquidation for each Fund (collectively, the "Plans"). Under the Plans, which are effective today, the Funds will begin the process of liquidating portfolio assets and unwinding their affairs in an orderly fashion over time. The Plans are not subject to shareholder approval. Shareholders of the Funds may sell their shares on the Funds' listing exchange, NYSE Arca, Inc. ("NYSE Arca"), u

      6/18/25 4:30:00 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • GridStor Promotes Daniel Dedrick to Chief Technology Officer, Creating New Role to Drive Growth

      Dedrick steps into the role with more than two decades of leadership in power sector engineering, technology, and project development GridStor, a developer and operator of utility-scale battery energy storage systems, announced today that Daniel Dedrick has been appointed as the company's chief technology officer (CTO). Dedrick has more than 20 years of experience leading power system engineering, technology development, and project development across multiple energy technologies. He joined GridStor in 2022 and served most recently as the company's senior vice president of engineering, procurement, and construction (EPC) and technical operations. "Daniel is one of the best technical strat

      4/10/25 9:00:00 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Fleetio Raises over $450 Million Series D and Acquires Auto Integrate to Create Customer-Centric One-Stop-Shop for Fleet Maintenance

      BIRMINGHAM, AL, March 25, 2025 (GLOBE NEWSWIRE) -- Fleetio, a leading fleet optimization software platform, today announced the acquisition of Auto Integrate, the premier maintenance authorization platform, in a landmark deal establishing Fleetio as a preferred solution for fleet maintenance. The company announced simultaneously the successful closing of over $450 million to finance the acquisition, valuing the combined business at over $1.5 billion. The round was co-led by existing Fleetio investor Elephant and new investor Growth Equity at Goldman Sachs Alternatives.   This strategic union creates a platform designed with customer-centricity to serve fleet operators of all sizes across

      3/25/25 11:00:00 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance

    $GS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Goldman Sachs Group Inc.

      SC 13G/A - GOLDMAN SACHS GROUP INC (0000886982) (Filed by)

      11/8/24 5:34:28 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Amendment: SEC Form SC 13G/A filed by Goldman Sachs Group Inc.

      SC 13G/A - GOLDMAN SACHS GROUP INC (0000886982) (Filed by)

      11/5/24 6:23:11 PM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance
    • Amendment: SEC Form SC 13G/A filed by Goldman Sachs Group Inc.

      SC 13G/A - GOLDMAN SACHS GROUP INC (0000886982) (Filed by)

      11/5/24 10:09:42 AM ET
      $GS
      Investment Bankers/Brokers/Service
      Finance